EKG Arrhythmias You Can’t Miss: SVT vs Afib vs Flutter vs VT (Management First) For Step 2

How Step 2 Wants You to Think: “Unstable vs Stable” Beats Perfect Rhythm Labels

If you only memorize EKG pictures, Step 2 will punish you with management questions where the “right rhythm” is less important than the right first action. The fastest way to win SVT vs atrial fibrillation vs flutter vs VT is to anchor on two decisions that appear in nearly every tachyarrhythmia stem: (1) Is the patient unstable? and (2) Is the QRS narrow or wide? This is why the classic board sequence is always: stabilize → classify → treat.

The high-yield trick: you can answer many questions without committing to the exact arrhythmia name. Example: “wide-complex tachycardia after prior MI, stable, BP okay.” Even if you’re unsure whether it is ventricular tachycardia or SVT with aberrancy, boards want you to treat it as VT because that’s the safer management path and the guideline-consistent default. The only time the exact label becomes mandatory is when the medication choice changes (e.g., AF with WPW where AV nodal blockers can precipitate VF).

EKG Pattern Recognition in 30 Seconds: What to Notice First

Step 2 stems often include a small strip that is intentionally “ugly”—baseline wander, few leads, and limited time. Build a fast scan order so you don’t overthink: Rate → Regularity → QRS width → Atrial activity → Context. Think of this like triage for your eyes: identify the features that change management immediately.

A practical Step 2 heuristic: if you can’t see clear P waves and the rhythm is narrow + irregular, assume AF and move to “rate vs rhythm vs anticoagulation.” If it’s narrow + regular at a high rate with sudden onset and no obvious flutter waves, assume SVT and reach for vagal maneuvers then adenosine (if stable). If it’s wide, behave like it’s VT until someone proves otherwise.

SVT on Step 2: What “Regular Narrow Tachycardia” Usually Means

On USMLE-style questions, “SVT” is often shorthand for AV nodal re-entrant tachycardia (AVNRT) or orthodromic AV re-entrant tachycardia (AVRT). The presentation is dramatic but stable: sudden palpitations, anxiety, lightheadedness, sometimes chest tightness, and a regular narrow tachycardia commonly 160–220. The exam wants you to apply the standard escalation: vagal maneuvers → adenosine → synchronized cardioversion (if unstable or refractory).

The adenosine question is a frequent testing point. Boards like to ask: “Regular narrow tachycardia, stable; next best step?” Choose vagal maneuvers if offered; otherwise adenosine. Another classic: “Adenosine transiently slows the ventricular rate but the tachycardia resumes.” That can still be SVT; adenosine has a very short half-life. Repeat dosing may appear, or the question may be hinting that the underlying rhythm is atrial flutter—adenosine may unmask flutter waves by increasing AV block. In that case, the correct pivot is to the flutter/AF pathway (rate control and anticoagulation considerations).

Finally, don’t miss the “why” behind vagal maneuvers: you are increasing parasympathetic tone to the AV node, slowing AV nodal conduction and interrupting AV node–dependent circuits. Step 2 doesn’t need electrophysiology depth, but it does love simple mechanism questions: “Which drug blocks AV nodal conduction and can terminate AVNRT?” → adenosine.

Atrial Fibrillation on Step 2: Rate Control, Rhythm Control, and Anticoagulation

Atrial fibrillation is the most testable irregular tachyarrhythmia because it forces you to integrate: hemodynamic stability, symptom duration, comorbidities, and thromboembolic risk. EKG is classically irregularly irregular with no discrete P waves. But Step 2 is less about “spot AF” and more about “what do you do first, safely.”

The anticoagulation logic is where many students bleed points. Step 2 generally expects you to use CHA₂DS₂-VASc to decide long-term stroke prevention (and sometimes to frame pericardioversion anticoagulation). You don’t need to compute every edge case perfectly to answer most questions; you need to recognize the “automatic anticoagulation” patterns: age ≥75, prior stroke/TIA, heart failure, hypertension, diabetes, and vascular disease each raise risk. When a vignette gives you those features, it is inviting anticoagulation as part of the plan.

Rhythm control (antiarrhythmics or ablation) is usually not the first move in typical Step 2 “new AF in the ED” questions unless the stem highlights severe symptoms despite rate control, tachycardia-induced cardiomyopathy, or a clear reversible trigger where early rhythm control is favored. More commonly, the test is satisfied with: rate control + anticoagulation assessment + treat the cause (thyrotoxicosis, infection, alcohol binge, PE, post-op stress).

Atrial Flutter vs Afib: How to Differentiate and Why Management Looks Similar (Until It Doesn’t)

Atrial flutter is often presented as AF’s “organized cousin.” The atria are not fibrillating chaotically; they are typically circling in a macro-reentrant loop (classically around the tricuspid annulus). The ventricular response is limited by the AV node, so you often see a regular ventricular rhythm at a predictable rate. The most common board presentation is 2:1 block with a ventricular rate near 150.

Where flutter becomes unique is in the “definitive therapy” conversation. Typical flutter circuits can be highly amenable to catheter ablation, and Step 2 may ask for long-term management in a patient with recurrent flutter despite rate control. Another nuance: flutter often conducts with fixed ratios (2:1, 3:1, variable). When the ratio changes, the ventricular rhythm becomes irregular, and flutter can mimic AF. This is why the board-safe approach is to treat the patient and the risk rather than to obsess over whether every flutter wave is visible.

The exam loves to connect flutter with structural heart disease or post-cardiac surgery settings, but you’re rarely asked to localize the circuit. More likely: “45-year-old with palpitations, sawtooth waves, stable.” If the answer choices include “diltiazem,” “metoprolol,” “synchronized cardioversion,” and “adenosine,” you decide based on stability and regularity. If stable, rate control wins; adenosine is not definitive for flutter, though it can be diagnostically useful.

Ventricular Tachycardia: Treat Wide-Complex as VT Until Proven Otherwise

Ventricular tachycardia (VT) is the “can’t miss” rhythm because the wrong medication can kill. Step 2 makes this simple: a wide-complex tachycardia is VT until you have strong evidence it’s not. Monomorphic VT is common in patients with prior MI and scar-related re-entry. Polymorphic VT includes torsades de pointes, often linked to prolonged QT and electrolyte or medication triggers.

One of the highest-yield medication safety points: don’t reflexively give diltiazem for a wide-complex tachycardia. If the rhythm is VT, AV nodal blockers won’t fix it and can worsen hemodynamics. Conversely, boards sometimes present a stable wide-regular tachycardia and offer procainamide vs amiodarone vs synchronized cardioversion. Choose cardioversion if there are instability features; otherwise select a guideline-consistent antiarrhythmic infusion and monitoring. If torsades is described (“twisting points,” long QT, syncope), magnesium is your first move.

Putting It Together: A USMLE-Style Management Matrix You Can Recreate From Memory

The fastest way to convert recognition into points is to memorize a small “matrix” of first-line actions. On exam day, you should be able to sketch this on your scratch paper in under 60 seconds: unstable vs stable; narrow vs wide; regular vs irregular. Below is a compact version that’s intentionally aligned with ACLS-style logic and common cardiology guideline framing.

If you want a practical way to drill this, build sets where you force yourself to answer in a single sentence: “Stable narrow irregular → rate control + anticoagulation decision.” “Unstable → synchronized cardioversion.” Repeating these one-liners is not simplistic—it mirrors how you must think under timed pressure.

Rapid-Review Checklist: The 12 Things to Know Before Your Next NBME Block

Use this list as a pre-block warm-up. If you can recite these rules and apply them to a messy strip, you’re in the “can’t miss” zone for SVT vs atrial fibrillation vs atrial flutter vs VT questions. Keep the wording tight, because that’s how the exam is written: short stems, high stakes, and only one “do this first” answer.

References

• American Heart Association. Adult Tachycardia With a Pulse Algorithm (ACLS).
• 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation (Circulation).
• ACC. Key Perspectives: 2023 AF Guideline (Ten Points to Remember).
• 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia.
• 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and Prevention of Sudden Cardiac Death.
• Joglar JA, et al. PubMed record for 2023 AF Guideline.

Medically reviewed by: Priya Shah, MD (Cardiology).